Newleos Therapeutics, Inc. — Form D
Newleos Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2025-02-24. The offering totals $93.4M, of which $93.4M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-02-24
- Form: D
- Accession: 0002057800-25-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $93.4M
- Amount sold: $93.4M
- Investors: 11
- Date of first sale: 2025-02-10
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-539081
Issuer
- Name: Newleos Therapeutics, Inc.
- CIK: 0002057800
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2024
- Address: C/O NEWLEOS THERAPEUTICS, INC., BOSTON, MA, 02199
- Phone: (617) 648-9100
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Raymond Camahort | Director | Boston, MA |
| Ming Cheah | Director | Boston, MA |
| David Donabedian | Director | Lowell, MA |
| Christoph Westphal | Director | CAMBRIDGE, MA |
| David Donabedian | Executive Officer | Lowell, MA |
| Robert Hadfield | Executive Officer | Boston, MA |
| John McCabe | Executive Officer | Boston, MA |
More